Home
HelpTest ID: GLIOF 1p/19q Deletion in Gliomas, FISH, Tissue
Useful For
Aids in diagnosing oligodendroglioma tumors and predicting the response of an oligodendroglioma to therapy
May be useful in tumors with a complex "hybrid" morphology requiring differentiation from pure astrocytomas to support the presence of oligodendroglial differentiation/lineage
Indicated when a diagnosis of oligodendroglioma, both low-grade World Health Organization (WHO, grade II) and anaplastic (WHO, grade III) is rendered
Strongly recommended when a diagnosis of mixed oligoastrocytomas is rendered
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| _I099 | Interphases, 25-99 | No, (Bill Only) | No |
| _I300 | Interphases, >=100 | No, (Bill Only) | No |
| _IL25 | Interphases, <25 | No, (Bill Only) | No |
| _PADD | Probe, +1 | No, (Bill Only) | No |
| _PB02 | Probe, +2 | No, (Bill Only) | No |
| _PB03 | Probe, +3 | No, (Bill Only) | No |
| _PBCT | Probe, +2 | No, (Bill Only) | No |
Testing Algorithm
This test does not include a pathology consult. If a pathology consultation is requested, PATHC / Pathology Consultation should be ordered, and the appropriate fluorescence in situ hybridization (FISH) test will be performed at an additional charge.
This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results. Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.
Appropriate ancillary probes may be performed at consultant discretion to render comprehensive assessment. Any additional probes will have the results included within the final report and will be performed at an additional charge.
Chromosomal microarray (CMAPT / Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded), rather than FISH, may be of benefit to evaluate for acquired alterations associated with the molecular classification of glioma.(1) For more information and frequently asked questions, see Clarity on Reason for and Benefits of Chromosomal Microarray.
Method Name
Fluorescence In Situ Hybridization (FISH) Using DNA Probes
Reporting Name
1p/19q Deletion, Glioma, FISH, TsSpecimen Type
TissueShipping Instructions
Advise Express Mail or equivalent if not on courier service.
Necessary Information
A reason for testing and pathology report are required in order for testing to be performed. Send information with specimen. Acceptable pathology reports include working drafts, preliminary pathology, or surgical pathology reports.
Specimen Required
Submit only 1 of the following specimens:
Specimen Type: Tissue
Preferred: Tissue block
Collection Instructions: Submit a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block. Blocks prepared with alternative fixation methods may be acceptable; provide fixation method used.
Acceptable: Slides
Collection Instructions: Six consecutive, unstained, 5 micron-thick sections placed on positively charged slides, and 1 hematoxylin and eosin-stained slide.
Specimen Minimum Volume
Four consecutive, unstained, 5-micron-thick sections placed on positively charged slides and 1 hematoxylin and eosin-stained slide
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Tissue | Ambient (preferred) | ||
| Refrigerated | |||
Clinical Information
Astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas are the major histologic types of human gliomas; histologic differentiation among these tumors can be difficult. It has been shown that specific genetic alterations are highly associated with specific morphologic types of gliomas. In addition, specific genetic alterations seem to predict prognosis (survival), as well as response to specific chemotherapeutic and radiotherapeutic regimens, irrespective of tumor morphology.
Deletions of the short arm of chromosome 1(1p) and long arm of chromosome 19 (19q), are strongly correlated with gliomas of oligodendroglial morphology. Approximately 70%, 50%, and 50% of oligodendrogliomas have deletions of 19q, 1p, and of both 19q and 1p, respectively.
Combined 1p and 19q loss is infrequent in gliomas of astrocytic origin. Thus, the presence of combined 1p/19q loss is strongly suggestive that a glioma is of oligodendroglioma lineage.
Gains of chromosome 19 and of the 19 q-arm are associated with gliomas of astrocytic origin.
Deletions of 1p and of both 1p and 19q also have been associated with response to various chemotherapeutic and radiotherapeutic regimens. These responses have been especially associated with high-grade oligodendrogliomas (anaplastic oligodendrogliomas).
Chromosomal microarray (CMAPT / Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded), rather than fluorescence in situ hybridization, may be of benefit to evaluate for acquired alterations associated with the molecular classification of glioma.(1) For more information and frequently asked questions, see Clarity on Reason for and Benefits of Chromosomal Microarray.
Reference Values
An interpretive report will be provided.
Interpretation
The presence of short arm of chromosome 1(1p) deletion and combined 1p and long arm of chromosome 19 deletion supports a diagnosis of oligodendroglioma may indicate that the patient may respond to chemotherapy and radiation therapy.
The presence of gain of chromosome 19 supports a diagnosis of high-grade astrocytoma (glioblastoma multiforme).
A negative result does not exclude a diagnosis of oligodendroglioma or high-grade astrocytoma.
Clinical Reference
1. WHO Classification of Tumours Editorial Board. Central Nervous System Tumours: WHO Classification of Tumours. Vol 6. 5th ed. IARC Press; 2022:19-55
2. Ball MK, Kollmeyer TM, Praska CE, et al. Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas. Neurooncol Adv. 2020 Aug 27;2(1):vdaa109. doi: 10.1093/noajnl/vdaa109
Day(s) Performed
Monday through Friday
Report Available
8 to 12 daysTest Classification
This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88271x2, 88291- DNA probe, each (first probe set), Interpretation and report
88271x2- DNA probe, each; each additional probe set (if appropriate)
88271x1- DNA probe, each; coverage for sets containing 3 probes (if appropriate)
88271x2- DNA probe, each; coverage for sets containing 4 probes (if appropriate)
88271x3- DNA probe, each; coverage for sets containing 5 probes (if appropriate)
88274- w/modifier 52- Interphase in situ hybridization, <25 cells, each probe set (if appropriate)
88274- Interphase in situ hybridization, 25 to 99 cells, each probe set (if appropriate)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| GLIOF | 1p/19q Deletion, Glioma, FISH, Ts | In Process |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 52107 | Result Summary | 50397-9 |
| 52109 | Interpretation | 69965-2 |
| 52108 | Result | 62356-1 |
| CG739 | Reason For Referral | 42349-1 |
| 52110 | Specimen | 31208-2 |
| 52111 | Source | 31208-2 |
| 52112 | Tissue ID | 80398-1 |
| 52113 | Method | 85069-3 |
| 54579 | Additional Information | 48767-8 |
| 53836 | Disclaimer | 62364-5 |
| 52114 | Released By | 18771-6 |
Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.
mml-neuro-oncology-oms